Effects of cerebellar TMS on cognitive functions in schizophrenia
Official title: Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Run by Northwell Health · NCT05389787 · Data updated 2026-11-12
This study is testing if a new brain treatment called rTMS can improve thinking skills in young adults with schizophrenia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Northwell Health Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | August 18, 2022 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT05389787 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are males and females aged 18 to 40 with a DSM-V diagnosis of schizophrenia spectrum disorders.
✕Probably not a fit
Patients with other significant psychiatric or neurological disorders, or those with contraindications to MRI, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study investigates the impact of repetitive transcranial magnetic stimulation (rTMS) on brain and cognitive functions in individuals aged 18 to 40 diagnosed with schizophrenia. A total of 60 participants will be randomly assigned to receive either active rTMS or sham rTMS alongside standard care for four weeks, with treatment sessions occurring five days a week. The study will utilize functional magnetic resonance imaging (fMRI) and cognitive assessments at baseline, mid-treatment, and post-treatment to evaluate changes in brain activity and cognitive performance.
Why it matters
Potential benefit: If successful, this study could lead to improved cognitive functioning and overall treatment outcomes for patients with schizophrenia.
How similar studies have gone: While the approach of using rTMS in schizophrenia is being explored, this specific application targeting cerebellar function is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female subjects 18 to 60 years of age 2. DSM-V diagnosis of schizophrenia spectrum disorders 3. Competent to provide informed consent Exclusion Criteria: 1. Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrum disorders 2. Lifetime diagnosis of ataxia or other cerebellar disorders 3. Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders 4. Any active general medical condition or CNS disease which can affect cognition or response to treatment 5. Substance dependence or abuse in the past six months 6. Seizure history 7. TMS within three months or ECT within six months 8. Pregnancy as indicated by self-report 9. MRI contraindications
Where it's running
-
Zucker Hillside Hospital
New York, New York, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Lumateperone to improve motivation in patients with schizophrenia and psychosis
This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
XEP527 in stable schizophrenia: safety and how it behaves in the body
This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.
-
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.
-
Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder
This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.
-
Neuronavigated rTMS for treatment-resistant auditory hallucinations
We are testing whether personalized neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations in adults who don’t respond to medication.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.